First Choice Neurology

Alzheimer’s clinical trial

Larger Clinical Trial for Alzheimer’s Drug Donanemab Starting Soon

Eli Lilly’s clinical trial of the experimental drug donanemab appears to have successfully slowed cognitive decline in patients with the early symptoms of Alzheimer’s. The TRAILBLAZER-ALZ clinical trial was a relatively small, placebo-controlled, double-blind, multi-center Phase 2 study measuring the safety, tolerability, and efficacy of donanemab in patients with early symptomatic Alzheimer’s. Clinical Trial Results …

Larger Clinical Trial for Alzheimer’s Drug Donanemab Starting Soon Read More »

BAN2401 Study to Assess New Alzheimer’s Treatment

If you or a loved one are experiencing signs of early Alzheimer’s disease, there may soon be treatment and hope on the horizon. First Choice Neurology is participating in an FDA-approved Phase III clinical trial to determine the benefit of an experimental product, BAN2401.   What is BAN2401 for Alzheimer’s? BAN2401 is a new class …

BAN2401 Study to Assess New Alzheimer’s Treatment Read More »

Biogen Seeks FDA Approval for New Alzheimer’s Drug

Biogen is planning to file for U.S. regulatory approval for its Alzheimer’s treatment aducanumab after data from more patients in two discontinued studies showed that the drug improved cognition at high doses. Patients who received aducanumab experienced significant benefits on measures of cognition and function such as memory, orientation, and language, Biogen said. In March, …

Biogen Seeks FDA Approval for New Alzheimer’s Drug Read More »

Translate »